KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Shares Outstanding (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Shares Outstanding for 13 consecutive years, with $54.7 million as the latest value for Q4 2023.

  • On a quarterly basis, Shares Outstanding rose 0.87% to $54.7 million in Q4 2023 year-over-year; TTM through Dec 2023 was $54.7 million, a 0.87% increase, with the full-year FY2023 number at $54.7 million, up 0.87% from a year prior.
  • Shares Outstanding was $54.7 million for Q4 2023 at Supernus Pharmaceuticals, up from $54.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $54.7 million in Q4 2023 to a low of $52.4 million in Q1 2019.
  • A 5-year average of $53.1 million and a median of $53.0 million in 2021 define the central range for Shares Outstanding.
  • Peak YoY movement for Shares Outstanding: rose 0.31% in 2020, then increased 1.87% in 2022.
  • Supernus Pharmaceuticals' Shares Outstanding stood at $52.5 million in 2019, then rose by 0.64% to $52.9 million in 2020, then rose by 0.73% to $53.3 million in 2021, then grew by 1.87% to $54.3 million in 2022, then increased by 0.87% to $54.7 million in 2023.
  • Per Business Quant, the three most recent readings for SUPN's Shares Outstanding are $54.7 million (Q4 2023), $54.3 million (Q4 2022), and $54.1 million (Q3 2022).